SCHEMBL5947423

SCHEMBL5947423

Oc1ccc2[nH]cc(CCNCc3cccc(OCC(F)(F)C(F)F)c3)c2c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 3/20 0.73
▸ HTR2A P28223 3/20 0.73
▸ HTR2C P28335 2/20 0.73
▸ HTR1A P08908 1/20 0.73
▸ DRD2 P14416 1/20 0.73
▸ HTR7 P34969 1/20 0.73
▸ KMT2A Q03164 2/20 0.52
▸ POLB P06746 1/20 0.48
▸ TRPV1 Q8NER1 2/20 0.47
▸ BCHE P06276 1/20 0.46
▸ LTA4H P09960 1/20 0.45
▸ PLA2G2A P14555 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ HDAC3 O15379 1/20 0.45
▸ HDAC4 P56524 1/20 0.45
▸ HDAC1 Q13547 1/20 0.45
▸ HDAC7 Q8WUI4 1/20 0.45
▸ HDAC2 Q92769 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5947174 0.93 HTR6 (0.82) HTR6HTR2AHTR2CHTR1ADRD2
SCHEMBL5148243 0.91 HTR2A (0.59) HTR6HTR2AHTR2CHTR1ADRD2
SCHEMBL5947556 0.90 HTR2A (0.74) HTR6HTR2AHTR2CHTR1ADRD2
SCHEMBL5947627 0.90 HTR2A (0.86) HTR6HTR2AHTR2CHTR1ADRD2
SCHEMBL5948031 0.89 HTR2A (0.71) HTR6HTR2AHTR2CHTR1ADRD2
SCHEMBL2540382 0.89 HTR2A (0.73) HTR6HTR2AHTR2CHTR1ADRD2
SCHEMBL5947337 0.89 HTR2A (0.73) HTR6HTR2AHTR2CHTR1ADRD2
SCHEMBL5947572 0.89 HTR2A (0.73) HTR6HTR2AHTR2CHTR1ADRD2
SCHEMBL5947881 0.89 HTR6 (0.81) HTR6HTR2AHTR2CHTR1ADRD2
SCHEMBL5947753 0.88 HTR2A (0.72) HTR6HTR2AHTR2CHTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US claimed
CN-1610547-A N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor LILLY CO ELI (US) 2005-04-27 — — CN claimed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 — — EP claimed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B HTR6 1/4885HTR2A 5/4885HTR2C 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback